Prelude Therapeutics (PRLD) News Today → These AI trades triggered this morning (545% return) (From Prosper Trading Academy) (Ad) Free PRLD Stock Alerts $4.07 +0.03 (+0.74%) (As of 04/26/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative SourceHeadlineSeveral Insiders Invested In Prelude Therapeutics Flagging Positive Newsfinance.yahoo.com - April 13 at 1:30 PMPrelude Highlights Continued Strength of Discovery Engine at 2024 AACR Annual Meetingglobenewswire.com - April 9 at 4:35 PMPrelude Therapeutics Inc Ordinary Shares PRLDmorningstar.com - March 30 at 11:31 PMPRLD Apr 2024 5.000 callfinance.yahoo.com - March 16 at 12:46 AMAnalysts Offer Insights on Healthcare Companies: Clearside Biomedical (CLSD) and Prelude Therapeutics (PRLD)markets.businessinsider.com - March 13 at 10:12 AMPrelude Therapeutics (NASDAQ:PRLD) Research Coverage Started at JMP Securitiesmarketbeat.com - March 13 at 8:17 AMFmr LLC Lowers Position in Prelude Therapeutics Incorporated (NASDAQ:PRLD)marketbeat.com - March 6 at 4:58 AMPrelude Announces Acceptance of Multiple Preclinical Abstracts at the 2024 AACR Annual Meetingglobenewswire.com - March 5 at 4:45 PMPrelude Therapeutics to Participate in Barclays Global Healthcare Conferenceglobenewswire.com - February 29 at 4:05 PMPrelude Therapeutics (NASDAQ:PRLD) Rating Lowered to Neutral at HC Wainwrightmarketbeat.com - February 20 at 7:32 AMHere's Why We're Watching Prelude Therapeutics' (NASDAQ:PRLD) Cash Burn Situationfinance.yahoo.com - February 17 at 12:25 PMNew Accounting & Financial Operations Risk for Prelude Therapeutics, Inc. – What’s the Latest?msn.com - February 17 at 7:22 AMPrelude Therapeutics Incorporated (NASDAQ:PRLD) Sees Significant Growth in Short Interestmarketbeat.com - February 16 at 7:17 PMPrelude Therapeutics files to sell 7.94M shares for holdersmsn.com - February 16 at 12:42 PMPrelude Therapeutics Incorporated Registered Shsmarkets.businessinsider.com - February 16 at 2:42 AMPrelude Therapeutics Reports Full Year 2023 Financial Results and Outlines Key Objectives for 2024finance.yahoo.com - February 15 at 8:51 PMPrelude Therapeutics Reports Full Year 2023 Financial Results and Outlines Key Objectives for 2024globenewswire.com - February 15 at 4:05 PMPrelude Therapeutics (NASDAQ:PRLD) Trading Up 8.3%marketbeat.com - February 15 at 2:41 AMPrelude Therapeutics: Interesting Pipeline That Is Too Early To Warrant My Buyseekingalpha.com - February 5 at 1:05 PMPrelude Therapeutics Incorporated (NASDAQ:PRLD) Short Interest Down 34.3% in Decembermarketbeat.com - January 14 at 7:58 PMPrelude Therapeutics Incorporated (NASDAQ:PRLD) is definitely on the radar of hedge funds investors who own 33% of the companyfinance.yahoo.com - January 14 at 2:13 PMMorgan Stanley Downgrades Prelude Therapeutics (PRLD)msn.com - December 19 at 5:56 PMMorgan Stanley Downgrades Prelude Therapeutics: Here's What You Need To Knowmarkets.businessinsider.com - December 19 at 12:51 PMPrelude Therapeutics Incorporated Common Stock (PRLD)nasdaq.com - December 18 at 8:14 PMPrelude Therapeutics Announces $25 Million Private Placementfinance.yahoo.com - December 11 at 12:56 PMPrelude Therapeutics Stock (NASDAQ:PRLD) Dividends: History, Yield and Datesbenzinga.com - November 20 at 3:08 PMPrelude Therapeutics Insiders Are Down US$149k But Regain Some Lossesfinance.yahoo.com - November 5 at 8:55 AMQ3 2023 Abcellera Biologics Inc Earnings Callfinance.yahoo.com - November 3 at 9:24 AMPrelude Announces Strategic Pipeline Progress and Updates, including its Partnership with AbCellera, and Reports Third Quarter Financial Resultsfinance.yahoo.com - November 1 at 7:26 PMPrelude Therapeutics and AbCellera Enter Partnership to Develop First-in-Class Precision Antibody Drug Conjugates in Oncologyfinancialpost.com - November 1 at 4:16 PMHC Wainwright & Co. Maintains Prelude Therapeutics (PRLD) Buy Recommendationmsn.com - October 19 at 5:00 PMThe Latest Analyst Ratings for Prelude Therapeuticsmarkets.businessinsider.com - October 19 at 12:00 PMPotential Upside in Prelude Therapeutics: A Focused Analysis on PRT2527 and PRT3789 Developmentmarkets.businessinsider.com - October 19 at 7:00 AMPrelude Announces Multiple Clinical and Preclinical Poster Presentations at AACR-NCI-EORTC International Conferencemarkets.businessinsider.com - October 14 at 3:31 PMPrelude Announces Multiple Clinical and Preclinical Poster Presentations at AACR-NCI-EORTC International Conferencefinance.yahoo.com - October 14 at 3:31 PMPrelude Therapeutics (PRLD) Price Target Increased by 11.70% to 10.71msn.com - October 6 at 12:57 AMAll You Need to Know About Prelude Therapeutics Incorporated (PRLD) Rating Upgrade to Buyfinance.yahoo.com - October 4 at 4:37 PMSHAREHOLDER ALERT: Kaskela Law LLC Announces Investigation of Prelude Therapeutics Inc. (NASDAQ: PRLD) and Encourages Investors to Contact the Firmbenzinga.com - October 2 at 12:54 PMBoxer Capital LLC Acquires Shares of 699,047 Prelude Therapeutics Incorporated (NASDAQ:PRLD)marketbeat.com - September 12 at 4:02 AMPrelude Therapeutics to Participate in Three Healthcare Investor Conferences in Septemberfinance.yahoo.com - August 29 at 8:56 AMPrelude Therapeutics to Participate in Three Healthcare Investor Conferences in Septemberfinance.yahoo.com - August 29 at 8:56 AMResearch Analysts Offer Predictions for Prelude Therapeutics Incorporated's Q3 2023 Earnings (NASDAQ:PRLD)marketbeat.com - August 21 at 1:28 AMHC Wainwright & Co. Reiterates Prelude Therapeutics (PRLD) Buy Recommendationmsn.com - August 17 at 9:19 PMH.C. Wainwright Sticks to Its Buy Rating for Prelude Therapeutics (PRLD)markets.businessinsider.com - August 17 at 9:41 AMPrelude Therapeutics (NASDAQ:PRLD) Receives "Equal Weight" Rating from Morgan Stanleymarketbeat.com - August 4 at 3:21 PMPrelude Therapeutics Announces Second Quarter 2023 Financial Results and Provides Corporate Updatefinance.yahoo.com - August 3 at 8:27 AMWe Think Prelude Therapeutics (NASDAQ:PRLD) Needs To Drive Business Growth Carefullyfinance.yahoo.com - July 10 at 9:50 AM8-K: Prelude Therapeutics Incmarketwatch.com - June 22 at 3:10 PMBoard Member at Prelude Therapeutics Acquires Company Stock Options Worth 47,000 Sharesbenzinga.com - June 22 at 3:10 PMPrelude Therapeutics Stock (NASDAQ:PRLD), Insider Trading Activitybenzinga.com - June 4 at 12:43 PM Get Prelude Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for PRLD and its competitors with MarketBeat's FREE daily newsletter. Email Address The “Next Bitcoin”? 10 CENT Crypto Set to Explode (Ad)The man who bought Bitcoin and Ethereum in 2017… and has spotted 44 different coins that have returned over 100%... Is now exposing a 10-cent coin that just partnered with Amazon… Click For My #1 FREE Crypto for 2024 PRLD Media Mentions By Week PRLD Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. PRLD News Sentiment▼0.000.32▲Average Medical News Sentiment PRLD News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. PRLD Articles This Week▼01▲PRLD Articles Average Week Get Prelude Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for PRLD and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: Merrimack Pharmaceuticals News Galectin Therapeutics News Generation Bio News Design Therapeutics News G1 Therapeutics News Foghorn Therapeutics News Immutep News Acrivon Therapeutics News Organigram News Rigel Pharmaceuticals News Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:PRLD) was last updated on 4/28/2024 by MarketBeat.com Staff From Our PartnersConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading AcademyHe Is Giving Away BitcoinCrypto Swap ProfitsBitcoin Rockets To Record High But Buy THIS InsteadParadigm PressThe A.I. story nobody is telling you (Read ASAP)TradeSmithProtect Your Bank Account Before It’s Too LateWeiss RatingsWhy Big Pharma is Investing Billions in This BiotechBehind the MarketsJeff Bezos Just Humiliated Elon MuskInvestorPlace Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Prelude Therapeutics Incorporated Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
